Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has successfully completed U.S. Food and Drug Administration (FDA) inspections at its Neuland and Aarau sites. The FDA conducted routine inspections over five days in Neuland from June 17-21, 2024, and three days in Aarau from June 24-26, 2024. The inspections concluded with no Form 483 observations or significant critical findings, affirming that N...